IIT, BHU to Re-Purpose Approved Drugs from Drug Bank Database for Treating COVOD-19

⪻ On New Articles ⪼

IIT, BHU to Re-Purpose Approved Drugs from Drug Bank Database for Treating COVOD-19

  • Support for research at IIT (BHU) has been approved by the Science and Engineering Research Board (SERB) .
  • It will help in identifying lead compounds from available and approved drugs for fats-track anti-SARS-CoV-2 drug molecule.
  • To deal with the pandemic which afflicts the world today, scientists and healthcare professionals worldwide are trying for a cure.
PIB, Science and Technology

Overview

  • Presently, available treatments are focused only on symptomatic relief to help the patient overcome the infection.
  • Repurposing of pre-existing drugs could help circumvent both the time and money required to find an effective cure.
  • The researchers are working to develop new drug candidates against SARS-CoV-2 by exploring Drug Bank database.
  • Drug Bank is a database of FDA approved drug compounds.
  • This database can be used for searching drug against SARS-CoV-2.
  • The database will be used to identify compounds as an inhibitor of SARS-CoV-2 main protease.
  • SARS-CoV-2 main protease is a key enzyme required for SARS-CoV-2 assembly and multiplication.
  • They will carry out extensive computational and experimental studies to identify an inhibitor of SARS-CoV-2 main protease.
  • The availability of crystal structure of SARS-CoV-2 is an added advantage.
  • This structure will be used by researchers to identify a structure based inhibitor design from the available FDA approved drugs compounds in Drug Bank database.
  • Subsequently, the designed inhibitor on recombinant SARS-CoV-2 will be experimentally validated using Mpro protein.
  • To establish the effectiveness of the inhibition of the SARS-CoV-2, various inhibitor parameters will be calculated.
  • Since the enzyme SARS-CoV-2 Mpro is key for processing and polyprotein for virus assembly, its inhibitor can have an anti-viral effect.
  • Most of the Drug Bank database compounds are characterized in terms of pharmacokinetics and toxicity, the identified molecule can be rapidly brought to the market.

Developed by: